We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Low Blood Glucose Level in Diabetics Tied to Hospital Readmission

By LabMedica International staff writers
Posted on 23 May 2019
More than 29 million Americans are living with diabetes and an additional 86 million are at risk for developing the disease, In hospitalized patients, low blood sugar, also known as hypoglycemia, is associated with increased short- and long-term mortality risk.

One complication of diabetes, hypoglycemia, occurs most often in people taking medications to manage their blood sugar. More...
These treatments can raise insulin levels too high, which can in turn cause blood glucose levels to drop too low. Hypoglycemia can be dangerous and, depending on the severity, can lead to various symptoms, including dizziness, confusion, anxiety, seizure or loss of consciousness.

Endocrinologists and their colleagues at the Baltimore Veterans Affairs Medical Center (Baltimore, MD, USA) investigated whether patients with diabetes and low glucose values during the last day of hospitalization are at increased risk of readmission or mortality. The evaluated readmission and death rates of more than 843,000 patients and found that low blood glucose levels were also associated with higher combined rates of 30-day readmission and mortality, and higher 30-, 90- and 180-day post-discharge mortality rates.

The investigators found that the rate ratios (RR) increased progressively for all five outcomes of interest (30-day readmission rate; 30-day, 90-day, and 180-day mortality rate; and combined 30-day readmission/mortality rate) as the minimum glucose concentrations progressively decreased below 90 to 99 mg/dL versus 100 to 109 mg/dL (30-day readmission RR, 1.01 to 1.45; 30-day readmission/mortality RR, 1.01 to 1.71; 30-day mortality RR, 0.99 to 5.82; 90-day mortality RR, 1.01 to 2.40; and 180-day mortality RR, 1.03 to 1.91). The 30-day readmission rate; 30-, 90-, and 180-day post-discharge mortality rate; and combined 30-day readmission/mortality rate were all greater for patients with diabetes with glucose levels <92.9 mg/dL; <45.2 mg/dL, 65.8 mg/dL, and 67.3 mg/dL; and <87.2 mg/dL, respectively.

The authors concluded that patients with diabetes who had hypoglycemia or near normal glucose values during the last day of hospitalization had higher rates of 30-day readmission and post discharge mortality. The study was published on May 1, 2019, in the Journal of Clinical Endocrinology & Metabolism.

Related Links:
Baltimore Veterans Affairs Medical Center


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.